MIGREN VA FIBROMIALGIYA PATOGENEZIDA: UMUMIY MEXANIZMLAR VA FARQLI XUSUSIYATLAR
##article.subject##:
Migren, fibromialgiya, markaziy sensibilizatsiya, neyroyallig’lanish, neyrotransmitter disbalansi##article.abstract##
Migren va fibromialgiya markaziy asab tizimining murakkab kasalliklari bo’lib, ular patofiziologik jihatdan o’xshash va o’ziga xos farqli xususiyatlarga ega. Ushbu kasalliklarning rivojlanishida umumiy patofiziologik mexanizmlar mavjud bo’lib, ular orasida markaziy sensibilizatsiya, neyrotransmitter disbalansi va neyroyallig’lanishi( neuroinflammation) jarayonlari asosiy o’rin egallaydi. Ushbu maqolada migren va fibromialgiyaning umumiy va farqli patogenetik mexanizmlari tahlil qilinadi. Ayniqsa, markaziy sensibilizatsiya, neyrotransmitter disbalansi va neyroinflamatsiya jarayonlarining ushbu kasalliklar rivojlanishida o’rni yoritiladi. Tadqiqot natijalari migren va fibromialgiya o’rtasidagi bog’liqlikni yanada chuqurroq tushunishga yordam beradi hamda diagnostika va davolash usullarini takomillashtirishda muhim ahamiyat kasb etadi.
Библиографические ссылки
Medical News Today. (2024). Migraines and fibromyalgia. Retrieved from https://www.medicalnewstoday.com/articles/migraines-and- fibromyalgia
Jahan, F., Nanji, K., Qidwai, W., & Qasim, R. (2012). Fibromyalgia syndrome: An overview of pathophysiology, diagnosis and management. Oman Medical Journal, 27(3), 192–195. https://doi.org/10.5001/omj.2012.44
Wolfe, F., Clauw, D. J., Fitzcharles, M. A., Goldenberg, D. L., Katz, R. S., Mease, P., Russell, A. S., Russell, I. J., & Winfield, J. B. (2010). The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care & Research, 62(5), 600–610. https://doi.org/10.1002/acr.20140
Wolfe, F., Clauw, D. J., Fitzcharles, M. A., Goldenberg, D. L., Häuser, W., Katz, R. L., Mease, P. J., Russell, A. S., Russell, I. J., & Walitt,
B. T. (2016). 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Seminars in Arthritis and Rheumatism, 46(3), 319–329. https://doi.org/10.1016/j.semarthrit.2016.08.012
Treede, R. D., Rief, W., Barke, A., Aziz, Q., Bennett, M. I., Benoliel, R., Cohen, M., Evers, S., Finnerup, N. B., First, M. B., Giamberardino,
M. A., Kaasa, S., Korwisi, B., Kosek, E., Lavand’homme, P., Nicholas, M., Perrot, S., Scholz, J., Schug, S., … Wang, S. J. (2019). Chronic pain as a symptom or a disease: The IASP classification of chronic pain for the International Classification of Diseases (ICD-11). Pain, 160(1), 19–27. https://doi.org/10.1097/j.pain.0000000000001384
Muir, W. W., & Woolf, C. J. (2001). Mechanisms of pain and their therapeutic implications. Journal of the American Veterinary Medical Association, 219(10), 1346–1356
Wager, T. D., Atlas, L. Y., Lindquist, M. A., Roy, M., Woo, C. W., & Kross, E. (2013). An fMRI-based neurologic signature of physical pain. New England Journal of Medicine, 368(15), 1388–1397. https://doi.org/10.1056/NEJMoa1204471
Harris, R. E., Sundgren, P. C., Craig, A. D., Kirshenbaum, E., Sen, A., Napadow, V., & Clauw, D. J. (2009). Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis & Rheumatism, 60(10), 3146–3152. https://doi.org/10.1002/art.24849
Harris, R. E., Sundgren, P. C., Pang, Y., Hsu, M., Petrou, M., Kim, S. H., McLean, S. A., Gracely, R. H., & Clauw, D. J. (2008). Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis & Rheumatism, 58(3), 903–907. https://doi.org/10.1002/art.23385
Russell, I. J., et al. (1992). Serotonin levels in fibromyalgia. Journal of Rheumatology, 19(1), 104–109.
Häuser, W., Urrútia, G., Tort, S., & Üçeyler, N. (2013). Efficacy of serotonin and norepinephrine reuptake inhibitors in fibromyalgia syndrome: A meta-analysis of randomized controlled trials. JAMA, 309(4), 374–382. https://doi.org/10.1001/jama.2012.211995
Wood, P. B., Patterson, J. C., 2nd, Sunderland, J. J., Tainter, K. H., Glabus, M. F., & Lilien, D. L. (2007). Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: A pilot study. Pain, 128(1–2), 264–268. https://doi.org/10.1016/j.pain.2007.02.031
Holman, A. J., & Myers, R. R. (2005). Pramipexole for fibromyalgia: A randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism, 52(8), 2495–2505. https://doi.org/10.1002/art.21253
Häuser, W., et.al.2012 Duloxetine and Milnacipran in Fibromyalgia. Cocchrane Database
Woolf, C. J. (2011). Central sensitization: Implications for the diagnosis and treatment of pain. Pain, 152(3 Suppl), S2–S15. https://doi.org/10.1016/j.pain.2010.09.030
Albrecht, D. S., et al. (2019). Brain glial activation in fibromyalgia. Brain, Behavior, and Immunity, 75, 222–227. https://doi.org/10.1016/j.bbi.2018.11.013
Kadetoff, D., Kosek, E., et al. (2012). Evidence of central inflammation in fibromyalgia: A positron emission tomography study. PLoS One, 7(5), e37533. https://doi.org/10.1371/journal.pone.0037533
Cordero, M. D., et al. (2016). Mitochondrial dysfunction in fibromyalgia: A possible role in pathophysiology and treatment. BBA Clinical, 6, 106–115. https://doi.org/10.1016/j.bbacli.2016.07.004
Ranzolin, A., Duarte, A. L. B. P., et al. (2018). Oxidative stress and fibromyalgia: A systematic review. Rheumatology International, 38(10), 1903–1919. https://doi.org/10.1007/s00296-018-4119-6
Clauw DJ. Fibromyalgia and related conditions. Mayo Clin Proc. 2015 May;90(5):680-92. doi: 10.1016/j.mayocp.2015.03.014. PMID: 25939940.
